Unicycive Therapeutics, Inc.
UNCYNasdaqCIK 1766140HealthcareFiscal year ends Dec 31
Reports and events: 103 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2907:46 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-104314 |
| 2026-09-2816:31 ET | 8-K | 8.01 Other events | 0001213900-26-104076 |
| 2026-08-1208:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-088061 |
| 2026-08-1206:30 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001213900-26-088013 |
| 2026-07-0210:30 ET | 8-K | 8.01 Other events | 0001213900-26-074678 |
| 2026-06-2206:05 ET | 8-K | 5.07 Shareholder vote results | 0001213900-26-070316 |
| 2026-06-0516:19 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-065828 |
| 2026-05-1207:51 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-054736 |
| 2026-05-1206:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001213900-26-054708 |
| 2026-04-3007:00 ET | DEF 14A | Proxy statementPeriod 2026-06-19 | 0001213900-26-049690 |
| 2026-04-0609:11 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-26-040179 |
| 2026-03-3007:29 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-035961 |
| 2026-03-3006:32 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001213900-26-035903 |
| 2025-11-1417:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-111045 |
| 2025-11-1209:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-108847 |
| 2025-11-1206:39 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001213900-25-108600 |
| 2025-10-2807:30 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-102790 |
| 2025-08-1816:17 ET | 8-K | 8.01 Other events | 0001213900-25-077937 |
| 2025-08-1516:30 ET | 8-K | 8.01 Other events | 0001213900-25-077497 |
| 2025-08-1408:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-076066 |
| 2025-08-1406:39 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001213900-25-076007 |
| 2025-07-0809:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-061936 |
| 2025-06-3009:25 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-059303 |
| 2025-06-2016:10 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-056188 |
| 2025-06-1009:29 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-052824 |
| 2025-06-0910:38 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-25-052413 |
| 2025-05-2109:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-046244 |
| 2025-05-1408:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-042967 |
| 2025-05-1407:05 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001213900-25-042943 |
| 2025-04-3016:06 ET | DEF 14A | Proxy statementPeriod 2025-06-09 | 0001213900-25-037613 |
| 2025-04-1416:30 ET | 8-K/A | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-25-031593 |
| 2025-03-3116:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-25-026270 |
| 2025-03-3109:15 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001213900-25-025828 |
| 2025-01-0716:15 ET | 8-K | 8.01 Other events | 0001213900-25-001640 |
| 2024-11-1308:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-24-097145 |
| 2024-11-1307:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001213900-24-097118 |
| 2024-11-1206:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-096104 |
| 2024-09-2520:54 ET | 8-K | 8.01 Other events | 0001213900-24-081531 |
| 2024-08-1408:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-24-068597 |
| 2024-08-1407:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001213900-24-068565 |
| 2024-07-1516:15 ET | 8-K | 3.01 Delisting notice | 0001213900-24-061355 |
| 2024-07-1516:15 ET | 8-K | 3.01 Delisting notice | 0001213900-24-061354 |
| 2024-07-0216:15 ET | 8-K | 1.01 Entry into a material agreement | 0001213900-24-058621 |
| 2024-06-2617:20 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001213900-24-056224 |
| 2024-06-2509:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-24-055436 |
| 2024-06-2016:05 ET | 8-K | 5.07 Shareholder vote results | 0001213900-24-054279 |
| 2024-05-1316:28 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-24-042338 |
| 2024-05-1316:06 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001213900-24-042298 |
| 2024-04-2617:10 ET | DEF 14A | Proxy statementPeriod 2024-06-20 | 0001213900-24-036716 |
| 2024-03-2917:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-24-027373 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 16:30 ET. Listed shows no prices and gives no investment advice.